#Israel #Salt Lake City #ARVO 2025 #Everads Therapy #Suprachoroidal Injector

Everads Therapy to Present Innovative Findings at ARVO 2025

Everads Therapy, a pioneer in the biotechnology sector, has exciting news. The company will present five significant research abstracts at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting to be held in Salt Lake City, Utah. Most notably, these abstracts include first-in-human data from their novel suprachoroidal delivery system, designed for the treatment of retinal diseases.

A New Era in Retinal Therapeutics

The Everads Suprachoroidal Injector stands out in its ability to provide effective and swift distribution of therapeutics across the suprachoroidal space. This innovative device utilizes a proprietary non-sharp tissue separator that facilitates access via blunt dissection. By allowing tangential delivery, this method ensures that medications reach the targeted regions of the back of the eye efficiently.

According to Moshe Weinstein, CEO of Everads Therapy, the results presented not only confirm the safety and performance of their delivery system but also pave the way for future collaborations and clinical programs. "The clinical data we are showcasing at ARVO supports our ambition to change the way retinal diseases are treated, utilizing a non-surgical approach that enhances patient safety and effectiveness," Weinstein stated.

Insights from Clinical Trials

The first-in-human study focused on assessing the Everads Injector's safety and efficacy in administering triamcinolone acetonide suspension to patients with diabetic macular edema (DME). Initial results indicate that this injector is not only safe but also user-friendly within outpatient environments. Dr. Yoreh Barak, the study's principal investigator and Head of Retina at Rambam Medical Center, emphasized that this technology could lead to less invasive interventions for posterior segment diseases, reshaping the landscape of eye care.

Presentations will delve deeper into various research angles, illustrating the versatility of Everads' platform across different therapeutic approaches. Some notable presentations include:

• - Ocular Pharmacokinetics and Tolerability of VVN481: This recent JAK inhibitor was tested following suprachoroidal delivery in rabbits.
• - First-in-Human Results of the Novel Suprachoroidal Delivery Injector: A thorough analysis conducted by Dr. Barak and his team.
• - Innovations in Pre-Clinical Evaluation: Examining minimally invasive suprachoroidal buckling techniques using their newly developed injector in human cadaver eyes.

The Future of Retinal Therapies

Everads Therapy's commitment to advancing retinal disease treatments extends beyond just the immediate findings. The company is continuously collaborating with several partners across gene therapy, small molecules, and other innovative modalities to maximize the use of its unique delivery approach.

Founded as a spin-off from DALI Medical Devices, Everads has roots in a pioneering medical technology background. Their entry into RAD Biomed, a notable biotech accelerator, underscores their commitment to transforming eye care.

The upcoming ARVO 2025 meeting offers a platform for Everads to not only share their groundbreaking results but also to engage with fellow professionals within the ophthalmology field. The data presented is expected to inspire collaborative efforts to enhance treatment options for patients globally.

For more details, you can visit Everads Therapy's official website and follow their updates on LinkedIn. The ARVO Annual Meeting serves as an ideal venue for showcasing advancements in eye research, and Everads is set to make a notable impact this year.